Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery

References

• KimSJFlachAJJampolLENonsteroidal anti-inflammatory drugs in ophthalmologySurv Ophthalmol201055210813320159228
   PubMed Web of Science ®Google Scholar
• KimSJBresslerNMOptical coherence tomography and cataract surgeryCurr Opin Ophthalmol2009201465119093330
   PubMed Web of Science ®Google Scholar
• KimSJEquiRBresslerNMAnalysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomographyOphthalmology2007114588188917275910
   PubMed Web of Science ®Google Scholar
• BelairMLKimSJThorneJEIncidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomographyAm J Ophthalmol2009148112813519403110
   PubMed Web of Science ®Google Scholar
• El HaraziSMRuizRSFeldmanRMVillanuevaGChuangAZA randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cellsOphthalmic Surg Lasers19882975395449674003
   PubMedGoogle Scholar
• FlachAJLavelleCJOlanderKWRetzlaffJASorensonLWThe effect of ketorolac tromethamine 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantationOphthalmology1988959127912843062540
   PubMed Web of Science ®Google Scholar
• FlachAJJaffeNSAkersWAThe effect of ketorolac tromethamine in reducing postoperative inflammation: Double-mask parallel comparison with dexamethasoneAnn Ophthalmol198921114074112619149
   PubMedGoogle Scholar
• OstrovCSSirkinSRDeutschWEMasiRJChandlerJWLindquistTDKetorolac, prednisolone, and dexamethasone for postoperative inflammationClin Ther19971922592729152565
   PubMed Web of Science ®Google Scholar
• HeierJCheethamJKDegryseRKetorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized vehicle-controlled clinical trialAm J Ophthalmol199927325325910088733
   PubMed Web of Science ®Google Scholar
• SimoneJNPendeltonRAJenkinsJEComparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgeryJ Cataract Refract Surg199925569970410330648
   PubMed Web of Science ®Google Scholar
• SnyderRWSiekertRWSchwiegerlingJDonnenfeldEThompsonPAcular as a single agent for use as an anti-miotic and anti-inflammatory in cataract surgeryJ Cataract Refract Surg20002681225122711008052
   PubMed Web of Science ®Google Scholar
• SolomonKDVromanDTBarkerDGehikenJComparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction; prospective, randomized, double masked studyJ Cataract Refract Surg2001271232237
   Google Scholar
• SolomonKDCheethamJKDeGryseRBrintSFRosenthalATopical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgeryOphthalmology2001108233133711158809
   PubMed Web of Science ®Google Scholar
• HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for the treatment of inflammation following phacoemulsification: A prospective, randomized, double-masked studyJ Cataract Refract Surg2002281939911777716
   PubMed Web of Science ®Google Scholar
• TrinivaratAAtchaneeyasakulLOSurachatkumtonekulTKosrirukvongsPComparison of topical prednisolone acetate, ketorolac tromethamine and fluorometholone acetate in reducing inflammation after phacoemulsificationJ Med Assoc Thai200386214315012678152
   PubMedGoogle Scholar
• PriceMOPriceFWEfficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgeryCurr Med Res Opin200420122015201915701218
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDPerryHDWittipenJRSolomonRChouTPreoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: Pharmacokinetic-response curveJ Cataract Refract Surg20063291474148216931258
   PubMed Web of Science ®Google Scholar
• SandovalHPDe CastroLEVromanDTSolomonKDEvaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantationJ Ocul Pharmacol Ther200622425125716910866
   PubMed Web of Science ®Google Scholar
• DuongHVWestfieldKCChalkleyTHKetorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trialJ Cataract Refract Surg200733111925192917964399
   PubMed Web of Science ®Google Scholar
• MacaSMAmonMFindiOKahramanGBarisani-AsenbauerTEfficacy and tolerability of preservative free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgeryAm J Ophthalmol2010149577778420152959
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDNichaminLDHardtenDRTwice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgeryAm J Ophthalmol2011151342042621145532
   PubMed Web of Science ®Google Scholar
• Acular [Package insert]Irvine, CAAllergan Inc1997
   Google Scholar
• Acular LS [Package insert]Irvine, CAAllergan Inc2008
   Google Scholar
• Acuvail [Package insert]Irvine, CAAllergan Inc2009
   Google Scholar
• AhujaMDhakeASSharmaSKMajumdarDKTopical ocular delivery of NSAIDsAAPS J200810222924118437583
   PubMed Web of Science ®Google Scholar
• WaltersTRaizmanMErnestPIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
   PubMed Web of Science ®Google Scholar
• BucciFAJrWaterburyLDAmicoLMProstaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsificationAm J Ophthalmol2007144114614717601444
   PubMed Web of Science ®Google Scholar
• SolomonKDDonnenfeldEDRaizmanMSafety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patientsJ Cataract Refract Surg20043081653166015313287
   PubMed Web of Science ®Google Scholar
• AttarMSchiffmanRBorbridgeLFarnesQWeltyDOcular pharmacokinetics of 0.45% ketorolac tromethamineClin Ophthalmol201041403140821179226
   PubMedGoogle Scholar
• WaterburyLDGalindoDVillanuevaLOcular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammationJ Ocul Pharmacol Ther201127217317821351868
   PubMed Web of Science ®Google Scholar
• GamacheDAGraffGBradyMTSpellmanJMYanniJMNepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacyInflammation200024435737010850857
   PubMed Web of Science ®Google Scholar
• WaterburyLDSillimanDJolasTComparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurr Med Res Opin20062261133114016846546
   PubMed Web of Science ®Google Scholar
• NordstromBLFriedmanDSMozaffariEPersistence and adherence with topical glaucoma therapyAm J Ophthalmol2005140459860616226511
   PubMed Web of Science ®Google Scholar
• FlachAJKraffMCSandersDRTanenbaumLThe quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrierArch Ophthalmol198810644804833355415
   PubMedGoogle Scholar
• McGheeCNWatsonDGMidgleyJMNobleMJDuttonGNFernAIPenetration of synthetic corticosteroids into human aqueous humourEye19944Pt 35265302209921
   PubMed Web of Science ®Google Scholar
• SamudreSSLattanzioFAJrWilliamsPBSheppardJDJrComparison of topical steroids for acute anterior uveitisJ Ocul Pharmacol Ther200420653354715684812
   PubMed Web of Science ®Google Scholar
• KimSJLoWRHubbardGB3rdTopical ketorolac in vitreoretinal surgery : A prospective, randomized, placebo-controlled, double-masked trialArch Ophthalmol200812691203120818779478
   PubMedGoogle Scholar
• RabiahPKFiscellaRGTesslerHHIntraocular penetration of periocular ketorolac and efficacy in experimental uveitisInvest Ophthalmol Vis Sci19963746136188595961
   PubMed Web of Science ®Google Scholar
• HeierJSAwhCCBusbeeBGVitreous nonsteroidal anti-inflammatory drug concentrations and prostaglandins E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%Retina20092991310131319934822
   PubMed Web of Science ®Google Scholar
• RezaeiKATomaHSCaiJPennJSSternbergPKimSJReduced choroidal neovascular membrane formation in cyclooxygenase-2 deficient miceInvest Ophthalmol Vis Sci201152270170720881304
   PubMed Web of Science ®Google Scholar
• ChinMSNagineniCNHooperLCDetrickBHooksJJCyclooxy-genase-2 gene expression and regulation in human retinal pigment epithelial cellsInvest Ophthalmol Vis Sci200142102338234611527948
   PubMed Web of Science ®Google Scholar
• MaloneySCFernandesBFCastiglioneEExpression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patientsRetina200929217618018827739
   PubMed Web of Science ®Google Scholar
• KimSJTomaHSInhibition of choroidal neovascularization by intra-vitreal ketorolacArch Ophthalmol2010128559660020457981
   PubMedGoogle Scholar
• BaklayanGAPattersonHMSongCK24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbitsJ Ocul Pharmacol Ther200824439239818665811
   PubMed Web of Science ®Google Scholar
• KimSJTomaHSBarnettJMPennJSKetorolac inhibits choroidal neovascularization by suppression of retinal VEGFExp Eye Res201091453754320659449
   PubMed Web of Science ®Google Scholar